Preventing the transmission of blood-borne viruses (BBV) such as HIV, hepatitis B and hepatitis C among people who inject drugs can have wide-reaching benefits: reducing health harms to individuals and subsequent costs to society.
This briefing helps local authorities and drug treatment and healthcare services to review their BBV prevention and treatment interventions for people who inject drugs. The content is drawn from published evidence, authoritative guidance, and feedback from drug treatment services.
